Drug Profile
Mitapivat - Agios Pharmaceuticals
Alternative Names: AG 348; AG 348-sulfate-hydrate; Mitapivat-sulfate; PYRUKYNDLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Class Antianaemics; Benzene derivatives; Cyclopropanes; Piperazines; Quinolines; Small molecules; Sulfonamides
- Mechanism of Action Pyruvate kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Inborn error pyruvate metabolism disorders
- Phase III Haemolytic anaemia; Thalassaemia
- Phase II/III Sickle cell anaemia
- Preclinical Hereditary spherocytosis
Most Recent Events
- 29 Feb 2024 Agios Pharmaceuticals plans a phase II trial for Sickle cell anaemia and Kidney disorders (In adolescents, In adults, In the elderly) (PO) in June 2024 (NCT06286046)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Inborn-error-pyruvate-metabolism-disorders(In volunteers) in USA (PO, Granules)
- 15 Feb 2024 Agios Pharmaceuticals announces intention to launch Mitapivat in the US for the treatment of thalassemia in 2025